Strongbridge Biopharma (NASDAQ: SBBP) is a biopharmaceutical company that focuses on the development, in-licensing, acquisition and commercialization of various complementary products and product candidates that target rare diseases in the United States and internationally. The company’s lead product candidate, COR-003 (levoketoconazole), is a cortisol inhibitor that is in the phase III trial for the treatment of endogenous Cushing’s syndrome. It is also developing COR-005 (veldoreotide), a novel somatostatin analog, which is in Phase II clinical development for the treatment of acromegaly. The company was formerly known as Cortendo plc and changed its name to Strongbridge Biopharma plc in September 2015. For more information, visit the company’s website at www.strongbridgebio.com.
About NetworkNewsWire
NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW is uniquely positioned to best serve private and public companies who need to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information, visit https://www.networknewswire.com
Please see full disclaimers on the NetworkNewsWire website: http://nnw.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
